A Review of Immune Checkpoint Blockade for the General Surgeon
Overview
Affiliations
The immune system is a complex and interconnected system that has evolved to protect its host from foreign pathogens. CD8 T cells are a type of immune cell that can be directly lethal to tumor cells. However, their tumor killing capabilities can be inhibited by checkpoint molecules. During the last decade, the development of medications that block these checkpoint molecules has revolutionized treatment for some cancer types and indications for use continue to grow. As usage of immunotherapy increases, toxicities and adverse events unique to immunotherapy are becoming more prevalent. Here, we review the commonly targeted inhibitory molecules along with their food and drug administration-approved indications in various cancer therapeutic regimens, immunotherapy-related toxicities, and how this may impact surgical planning.
Myers S, Downs-Canner S Ann Surg Oncol. 2024; 31(8):5205-5206.
PMID: 38776008 DOI: 10.1245/s10434-024-15445-z.
Myers S, Sevilimedu V, Jones V, Abuhadra N, Montagna G, Plitas G Ann Surg Oncol. 2024; 31(8):5180-5188.
PMID: 38767803 DOI: 10.1245/s10434-024-15359-w.
Structural basis for the activity and specificity of the immune checkpoint inhibitor lirilumab.
Lorig-Roach N, Harpell N, DuBois R Sci Rep. 2024; 14(1):742.
PMID: 38185735 PMC: 10772121. DOI: 10.1038/s41598-023-50262-6.
Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future.
Liu Y World J Gastroenterol. 2023; 29(34):5020-5037.
PMID: 37753366 PMC: 10518742. DOI: 10.3748/wjg.v29.i34.5020.